K-V PHARMACEUTICAL 'HOLD,' TARGET PRICE REDUCED

June 16, 2006

Analysts at Deutsche Bank Securities maintain their "hold" rating on K-V Pharmaceutical. The target price has been reduced from $26 to $20.
Newratings

KEYWORDS Daily International Pharma Alert

FDA Recommends Modified COVID-19 Vaccine Boosters Adapted to Omicron BA.4 and BA.5 Subvariants

K-V PHARMACEUTICAL 'HOLD,' TARGET PRICE REDUCED

Upcoming Events

FDA Ad and Promo Enforcement Trends: Past, Present and Future

Applying the Lessons of the Pandemic to Your Upcoming Trial

EU-MDR’s Growing Pains: Are You Current with the Latest Developments?

Is Your Product a Drug or Device — and Does It Matter?: A Recent Appeals Court Decision Says It Does

Medical Device Cybersecurity: Understand the Latest Developments

Pharmaceutical Process Validation: Best Practices for Success

Featured Products

FDA’s New Quality System Regulation: Transitioning from QSR to ISO 13485

Selecting and Implementing Electronic Document Management Systems in the EU

Featured Stories

FX Receives FDA Clearance for Its FX V135 Shoulder Arthroplasty Platform

FDA Recommends Modified COVID-19 Vaccine Boosters Adapted to Omicron BA.4 and BA.5 Subvariants

FDA Approves Foundation Medicine’s Companion Diagnostic for Genentech’s Rozlytrek

Novartis Pays $100 Million for Mallinckrodt’s Priority Review Voucher

The Revised ICH E8: A Guide to New Clinical Trial Requirements